Latest Breaking News On - Ilya rachman - Page 1 : comparemela.com

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesMike moyerGabriel morrisIlya rachmanPolina stepenskyView researchCompany contactCompany annual report on formHadassah medical organizationDepartment of bone marrow transplantationAmerican society of geneGlobenewswire incBaltimore convention centerExchange commissionImmix biopharma incYork heart association

NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma

The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.

Ilya rachmanGabriel morrisDrug administrationImmix biopharma incEuropean unionInternational myeloma society annual meetingNexcella incInternational myeloma working group uniform response criteriaEuropean commissionImmix biopharmaInternational myeloma society annualSingle dayAnnual meetingMyeloma society annual meetingNxc 201 receives orphan drug designationNxc 201

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

European Orphan Drug Designation qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol.

Gabriel morrisMike moyerIlya rachmanEuropean commissionExchange commissionCompany annual report on formEuropean medicines agencyEuropean unionCommittee for orphan medicinal productsImmix biopharma incCompany contactEuropean orphan drug designationChief executive officerChief financial officerImmix biopharmaSingle day

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S..

United statesNew yorkIlya rachmanMike moyerExchange commissionCompany annual report on formCompany contactImmix biopharma incEuropean commissionNew york cityImmix biopharmaOrphan drug designationAnnual report

Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States

Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMike moyerIlya rachmanEuropean commissionCompany annual report on formExchange commissionImmix biopharma incCompany contactImmix biopharma subsidiaryNew york cityImmix biopharmaExecutive chairmanOrphan drug designationAnnual report